112
Participants
Start Date
March 17, 2021
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
Selinexor
Unit Dose Strength: 20 mg; Dose Formulation: Tablet; Dosage Level: 60 or 80 mg, QW; Route of Administration: Oral
Physician's Choice Treatment
Physician's choice treatment may include ruxolitinib retreatment, fedratinib, chemotherapy (e.g., hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulatory agent, androgen, interferon (all as per clinical practice) and may include supportive care only with no MF treatment; no investigational therapies are allowed.
Azienda Unita Sanitaria Locale Latina - Ospedale Santa Maria Goretti, Latina
University of Perugia Department of Medicine Hematology Section, Perugia
"University General Hospital ATTIKON", Athens
Asst Settelaghi, Ospedale Di Circolo E Fondazione Macchi, Varese
Hospital Universitario 12 de Octubre, Madrid
Institut de Cancéro-Hématologie, Brest
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola
Centre Hospitalier Universitaire d'Angers (CHU Angers), Angers
Università degli Studi di Firenze - Azienda Ospedaliero - Universitaria Careggi - Dipartimento di medicina sperimentale e clinica, Florence
Illinois Cancer Specialist, Niles
Texas Oncology - Northeast Texas, Tyler
Rocky Mountain Cancer Centers, LLP, Aurora
The Oncology Institute of Hope and Innovation, Pasadena
Peking Union Medical College Hospital, Beijing
The First Hospital of Jilin University, Changchun
The Second Affiliated Hospital of Soochow University, Suzhou
Suzhou University -The First Affiliated Hospital, Suzhou
Affiliated Hospital of Nantong University, Nantong
Sir Run Run Shaw Hospital - Zhejiang University School of Medicine, Hangzhou
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Pratia Onkologia Katowice, Katowice
Lead Sponsor
Karyopharm Therapeutics Inc
INDUSTRY